RxDoctor Payments Data

Natalie Hall

Women's Health · Mount Airy, NCNPI 1154512820

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.4% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Astellas Pharma US Inc at 24.1% of the total.

$1,832in general payments, 2019–2025

Across 98 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$442
  • AbbVie$286
  • Mayne Pharma Commercial LLC$227
  • Takeda Pharmaceuticals U.S.A., Inc.$109
  • Exeltis, USA Inc.$105
  • Novo Nordisk$80
  • plus $584 from 16 others

What the payments were for

  • Food & beverage$1,74795%
  • Education$855%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,832 in reported general payments places this provider in the 85th percentile of 158 women's health providers in North Carolina.

See all women's health providers in North Carolina

Medicare billing

Part B allowed, 2024
$6,011
Medicare patients
43
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated13$6,186
Estradiol50$1,713
ProgesteroneProgesterone, Micronized34$1,176
Clobetasol Propionate14$386
Nystatin20$321
Fluconazole19$117
Triamcinolone Acetonide11$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$57$6,18613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 158 women's health providers in North Carolina.

Other women's health in Mount Airy

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →